NCT07293247ClinicalTrials.gov
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-PORT) for Resected Non-Small Cell Lung Cancer With Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)
باختصار
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining…
المرحلة 2مطلوب 164 مشاركاً125 موقعاًدولة واحدة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07293247فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل أسبوعين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-12-19; recorded start 2026-10-14
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 97 other studies in this databaseCounted from the lead sponsor named in the record (Alliance for Clinical Trials in Oncology)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: other.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding0/20
Open-label
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 33 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A small study: 164 participants (target), run at 125 sites.
How this score is built
- Enrolment21/40
164 participants (target)
- Site count18/25
33 sites
- Country count0/15
Single country
- Planned duration10/10
Planned over about 69 months
- Sponsor scale7/10
Alliance for Clinical Trials in Oncology has led 96 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining lymph node cancer after surgery. Radiation therapy uses high-energy X-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Intensity-modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding I²-PORT radiation therapy to standard therapy may be more effective than standard therapy alone in reducing the risk of cancer returning in those who have undergone surgery for NSCLC.
الحالات
- Lung Non-Small Cell Carcinoma
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 2 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | NONE (0) |
| التجنيد | مطلوب 164 مشاركاً |
الجهة الراعية والمتعاونون
- Alliance for Clinical Trials in Oncology الجهة الراعية
- National Cancer Institute (NCI) المتعاونون
الأذرع والتدخلات
- Arm I (SOC chemotherapy/immunotherapy)ACTIVE_COMPARATOR
Patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.
- Arm II (I²-PORT, SOC chemotherapy/immunotherapy)EXPERIMENTAL
Patients undergo I²-PORT QD Monday through Friday over 15-25 fractions over 5-6 weeks. Starting 1-42 days after completion of I²-PORT, patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.
التدخلات
- إجراء Biospecimen Collection
Undergo blood sample collection
- دواء Chemotherapy
Receive standard of care chemotherapy
- إجراء Computed Tomography
Undergo CT
- أخرى Fludeoxyglucose F-18
Undergo FDG PET scan
- أخرى Immunotherapy
Receive standard of care immunotherapy
- إشعاع Intensity-Modulated Radiation Therapy
Undergo I²-PORT
- إجراء Magnetic Resonance Imaging
Undergo MRI
مقاييس النتائج
مقياس النتيجة الأولي
Disease-free survival (DFS)
DFS will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. The median DFS for each treatment group will be estimated, and its 80% and 90% confidence intervals will be calculated using the Kaplan-Meier estimator. Additionally, the 24-month DFS rate for each treatment arm, along with its confidence intervals, will be calculated.
الإطار الزمني Time from the date of randomization to the date of earliest disease recurrence/progression or deaths of all causes, assessed up to 5 years
مقياس النتيجة الأولي
Incidence of late grade ≥ 3 cardiopulmonary toxicities
Will be assessed according to the Common Terminology Criteria for Adverse Events version 5.0. Will be estimated for each treatment group and the difference between the two treatment groups. The confidence intervals of the rate difference at 80% and 90% significance levels will be estimated using the Miettinen-Nurminen method.
الإطار الزمني Between 3 and 24 months after protocol therapy
مقياس النتيجة الثانوي
5-year DFS
DFS will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1
الإطار الزمني Time from the date of randomization to the date of earliest disease recurrence/progression or deaths of all causes, assessed up to 5 years
مقياس النتيجة الثانوي
2-year overall survival (OS)
Will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. Multivariable Cox models will evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, pre-treatment, histology, and performance status.
الإطار الزمني Time from the date of randomization to death from all causes, assessed up to 2 years
مقياس النتيجة الثانوي
5-year OS
Will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. Multivariable Cox models will evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, pre-treatment, histology, and performance status.
الإطار الزمني Time from the date of randomization to death from all causes, assessed up to 5 years Symptomatic skeletal event free survival (SSE-FS)
مقياس النتيجة الثانوي
Patient-reported symptoms
Will be assessed using Patient Reported Outcomes - Common Terminology Criteria for Adverse Events and will be evaluated for between-arm differences in proportions of patients with a maximum post-baseline score greater than 0 using Fisher's exact or chi-square test.
الإطار الزمني up to 5 years
التواريخ
| تاريخ البدء | 14 أكتوبر 2026 (تقديري) |
|---|---|
| الإتمام الأولي | 31 ديسمبر 2032 (تقديري) |
| الإتمام | 1 مارس 2036 (تقديري) |
| أول نشر | 19 ديسمبر 2025 (فعلي) |
| آخر تحديث | 3 نوفمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | نوفمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
121 موقعاً قيد التجنيد
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor | Michigan | قيد التجنيد |
| Northwest Wisconsin Cancer Center | Ashland | Wisconsin | قيد التجنيد |
| Duluth Clinic Ashland | Ashland | Wisconsin | قيد التجنيد |
| Mount Sinai Comprehensive Cancer Center at Aventura | Aventura | Florida | قيد التجنيد |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | قيد التجنيد |
| MaineHealth Coastal Cancer Treatment Center | Bath | Maine | قيد التجنيد |
| UPMC-Heritage Valley Health System Beaver | Beaver | Pennsylvania | قيد التجنيد |
| Sanford Joe Lueken Cancer Center | Bemidji | Minnesota | قيد التجنيد |
| Sanford Bismarck Medical Center | Bismarck | North Dakota | قيد التجنيد |
| Illinois CancerCare-Bloomington | Bloomington | Illinois | قيد التجنيد |
| OSF Saint Joseph Medical Center | Bloomington | Illinois | قيد التجنيد |
| Essentia Health Saint Joseph's Medical Center | Brainerd | Minnesota | قيد التجنيد |
| Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Michigan | قيد التجنيد |
| Trinity Health Medical Center - Brighton | Brighton | Michigan | قيد التجنيد |
| MaineHealth Cancer Care and IV Therapy - Brunswick | Brunswick | Maine | قيد التجنيد |
| Trinity Health Medical Center - Canton | Canton | Michigan | قيد التجنيد |
| Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton | Michigan | قيد التجنيد |
| Illinois CancerCare-Canton | Canton | Illinois | قيد التجنيد |
| Saint Francis Medical Center | Cape Girardeau | Missouri | قيد التجنيد |
| Carlisle Regional Cancer Center | Carlisle | Pennsylvania | قيد التجنيد |
| Illinois CancerCare-Carthage | Carthage | Illinois | قيد التجنيد |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | قيد التجنيد |
| Medical University of South Carolina | Charleston | South Carolina | قيد التجنيد |
| Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Michigan | قيد التجنيد |
| Chelsea Hospital | Chelsea | Michigan | قيد التجنيد |
| Rush MD Anderson Cancer Center | Chicago | Illinois | قيد التجنيد |
| Clackamas Radiation Oncology Center | Clackamas | Oregon | قيد التجنيد |
| Baptist Memorial Hospital and Cancer Center-Collierville | Collierville | Tennessee | قيد التجنيد |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | قيد التجنيد |
| Memorial Sloan Kettering Commack | Commack | New York | قيد التجنيد |
| Cancer Care Specialists of Illinois - Decatur | Decatur | Illinois | قيد التجنيد |
| Decatur Memorial Hospital | Decatur | Illinois | قيد التجنيد |
| Essentia Health - Deer River Clinic | Deer River | Minnesota | قيد التجنيد |
| Essentia Health Cancer Center | Duluth | Minnesota | قيد التجنيد |
| Miller-Dwan Hospital | Duluth | Minnesota | قيد التجنيد |
| Essentia Health Saint Mary's Medical Center | Duluth | Minnesota | قيد التجنيد |
| Duke University Medical Center | Durham | North Carolina | قيد التجنيد |
| Marshfield Medical Center-EC Cancer Center | Eau Claire | Wisconsin | قيد التجنيد |
| UPMC Hillman Cancer Center Erie | Erie | Pennsylvania | قيد التجنيد |
| Illinois CancerCare-Eureka | Eureka | Illinois | قيد التجنيد |
| Sanford Roger Maris Cancer Center | Fargo | North Dakota | قيد التجنيد |
| Sanford Broadway Medical Center | Fargo | North Dakota | قيد التجنيد |
| Parkland Health Center - Farmington | Farmington | Missouri | مُعلَّق |
| UPMC Cancer Center at UPMC Horizon | Farrell | Pennsylvania | قيد التجنيد |
| Illinois CancerCare-Galesburg | Galesburg | Illinois | قيد التجنيد |
| UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg | Pennsylvania | قيد التجنيد |
| UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg | Pennsylvania | قيد التجنيد |
| Memorial Sloan Kettering Westchester | Harrison | New York | قيد التجنيد |
| Essentia Health-Hayward Clinic | Hayward | Wisconsin | قيد التجنيد |
| Essentia Health Hibbing Clinic | Hibbing | Minnesota | قيد التجنيد |
يُدرَج 75 موقعاً إضافياً في سجل السجل.
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 3 نوفمبر 2026
أُضيف موقع
14 sites added (125 total)
111125
- 19 أكتوبر 2026
تأخّر تاريخ الإتمام
Primary completion delayed 1461 days
2028-12-312032-12-31
- 2 أكتوبر 2026
أُضيف موقع
14 sites added (111 total)
97111
- 2 سبتمبر 2026
أُضيف موقع
23 sites added (97 total)
7497
- 5 أغسطس 2026
أُضيف موقع
41 sites added (74 total)
3374